StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30136% above fair value
$163.81−6.48 (-3.81%)

Close on Nov 20, 2026Market cap $10.47BP/E –Yield –

Repligen shares outstanding

Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.

Repligen's shares outstanding was 57M at Sep 30, 2026. For fiscal 2025 it was 0M, up 1.1% from the year before. Over ten years it grew -47.2% a year on average. The highest annual figure on record is 49M in fiscal 2019.

Annual shares outstanding

PeriodPeriod endValueChange
FY2025Dec 31, 20250M+1.1%
FY2024Dec 31, 20240M-0.8%
FY2023Dec 31, 20230M-1.9%
FY2022Dec 31, 20220M+0.3%
FY2021Dec 31, 20210M+6.3%
FY2020Dec 31, 20200M-99.9%
FY2019Dec 31, 201949M+8.2%
FY2018Dec 31, 201845M+16.1%
FY2017Dec 31, 201739M+114712.8%
FY2016Dec 31, 20160M-99.9%
FY2015Dec 31, 201534M+0.9%
FY2014Dec 31, 201433M+2.6%
FY2013Dec 31, 201332M+5.3%
FY2011Mar 31, 201131M+0.1%
FY2010Mar 31, 201031M–

Quarterly shares outstanding

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 202657M+0.0%
Q2 FY2026Jun 30, 202657M+0.2%
Q1 FY2026Mar 31, 202657M+0.2%
Q4 FY2025Dec 31, 20250M+3.4%
Q3 FY2025Sep 30, 202557M+100828.4%
Q2 FY2025Jun 30, 202557M+100034.7%
Q1 FY2025Mar 31, 202557M+99947.8%
Q4 FY2024Dec 31, 20240M+0.2%
Q3 FY2024Sep 30, 20240M-1.6%
Q2 FY2024Jun 30, 20240M-0.7%
Q1 FY2024Mar 31, 20240M-0.9%
Q4 FY2023Dec 31, 20230M-4.1%
Q3 FY2023Sep 30, 20230M-0.6%
Q2 FY2023Jun 30, 20230M+0.2%
Q1 FY2023Mar 31, 20230M-3.0%
Q4 FY2022Dec 31, 20220M-1.4%
Q3 FY2022Sep 30, 20220M-0.1%
Q2 FY2022Jun 30, 20220M-0.1%
Q1 FY2022Mar 31, 20220M+3.4%
Q4 FY2021Dec 31, 20210M-99.9%
Q3 FY2021Sep 30, 20210M-99.9%
Q2 FY2021Jun 30, 20210M-99.9%
Q1 FY2021Mar 31, 20210M-99.9%
Q3 FY2020Sep 30, 202053M+3.2%
Q2 FY2020Jun 30, 202053M+8.7%
Q1 FY2020Mar 31, 202053M+14.8%
Q4 FY2019Dec 31, 201953M+115624.0%
Q3 FY2019Sep 30, 201952M+114990.2%
Q2 FY2019Jun 30, 201949M+110568.4%
Q1 FY2019Mar 31, 201946M+4.3%
Q3 FY2018Sep 30, 20180M-99.9%
Q2 FY2018Jun 30, 20180M-99.9%
Q1 FY2018Mar 31, 20180M-99.9%
Q4 FY2017Dec 31, 201744M+29.1%
Q3 FY2017Sep 30, 201743M–
Q2 FY2017Jun 30, 201735M–
Q1 FY2017Mar 31, 201734M–
Q4 FY2016Dec 31, 201634M–

More Repligen figures

See a number that looks wrong?